[{"id":"2fe6f15d-ce95-4e79-99e5-0f49a12d649f","acronym":"SPEAR","url":"https://clinicaltrials.gov/study/NCT05022342","created_at":"2021-08-26T12:53:00.483Z","updated_at":"2024-07-02T16:35:43.630Z","phase":"","brief_title":"Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-world","source_id_and_acronym":"NCT05022342 - SPEAR","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2 • ER • PIK3CA • PGR","pipe":" | ","alterations":" HR positive • HER-2 negative • PIK3CA mutation • PIK3CA H1047R • PIK3CA E545K • PIK3CA E545 • PIK3CA E542 • PIK3CA H1047L • PIK3CA C420R • PIK3CA E545A • PIK3CA E545G • PIK3CA Q546 • PIK3CA Q546R","tags":["HER-2 • ER • PIK3CA • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • PIK3CA mutation • PIK3CA H1047R • PIK3CA E545K • PIK3CA E545 • PIK3CA E542 • PIK3CA H1047L • PIK3CA C420R • PIK3CA E545A • PIK3CA E545G • PIK3CA Q546 • PIK3CA Q546R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib) • fulvestrant"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 10/27/2021","start_date":" 10/27/2021","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2023-07-07"},{"id":"652d5ab0-cd46-459c-90cb-214f85150b09","acronym":"","url":"https://clinicaltrials.gov/study/NCT02688881","created_at":"2021-01-18T13:06:49.957Z","updated_at":"2024-07-02T16:36:08.876Z","phase":"Phase 4","brief_title":"Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors","source_id_and_acronym":"NCT02688881","lead_sponsor":"Samsung Medical Center","biomarkers":" PIK3CA • PTEN","pipe":" | ","alterations":" PIK3CA mutation • PIK3CA H1047R • PIK3CA E545K • PIK3CA amplification • PIK3CA E542K • PIK3CA E545 • PIK3CA E542 • AKT1 amplification","tags":["PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • PIK3CA H1047R • PIK3CA E545K • PIK3CA amplification • PIK3CA E542K • PIK3CA E545 • PIK3CA E542 • AKT1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 02/05/2017","start_date":" 02/05/2017","primary_txt":" Primary completion: 12/30/2020","primary_completion_date":" 12/30/2020","study_txt":" Completion: 02/24/2021","study_completion_date":" 02/24/2021","last_update_posted":"2022-06-15"},{"id":"2d198776-2ccc-4054-a157-17cc649e6945","acronym":"NRG-GY008","url":"https://clinicaltrials.gov/study/NCT02728258","created_at":"2021-01-18T13:21:19.164Z","updated_at":"2024-07-02T16:36:17.078Z","phase":"Phase 2","brief_title":"Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer","source_id_and_acronym":"NCT02728258 - NRG-GY008","lead_sponsor":"NRG Oncology","biomarkers":" PIK3CA","pipe":" | ","alterations":" PIK3CA mutation • PIK3CA H1047R • PIK3CA E545K • PIK3CA E545 • PIK3CA E542 • PIK3CA H1047L • PIK3CA M1043I • PIK3CA C420R • PIK3CA E545A • PIK3CA N345K • PIK3CA E545G • PIK3CA E545X • PIK3CA G1049R • PIK3CA H1047X • PIK3CA Q546 • PIK3CA Q546K • PIK3CA Q546R","tags":["PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • PIK3CA H1047R • PIK3CA E545K • PIK3CA E545 • PIK3CA E542 • PIK3CA H1047L • PIK3CA M1043I • PIK3CA C420R • PIK3CA E545A • PIK3CA N345K • PIK3CA E545G • PIK3CA E545X • PIK3CA G1049R • PIK3CA H1047X • PIK3CA Q546 • PIK3CA Q546K • PIK3CA Q546R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aliqopa (copanlisib)"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 09/16/2016","start_date":" 09/16/2016","primary_txt":" Primary completion: 08/18/2018","primary_completion_date":" 08/18/2018","study_txt":" Completion: 02/14/2020","study_completion_date":" 02/14/2020","last_update_posted":"2022-02-15"}]